Product Wiki · Recalls · Health Canada — Medical Devices

Tempus Pro Monitor — recall 77326

Health Canada — Medical Devices · Canada · 2025-04-25 · Type I

Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Agency
Health Canada — Medical Devices
Recall identifier
77326
Date of alert
2025-04-25
Country / jurisdiction
Canada
Risk level
Type I
Risk type
recall
Product category
Cardiovascular
Product type
Medical devices
Reported risk: i. The device may fail to startup normally, freeze, or reboot. error messages may be displayed, resulting in the device becoming inoperable. These issues could occur during startup or clinical use in the following ways: The Tempus Pro monitor may freeze at the startup screen, display an "mpm application" software error message, or may show an "attention-restart required" message. The Tempus Pro monitor may freeze and automatically reboot either when the user starts the process of recording a 12-lead ECG (by pressing the "start record" button) or after the 12-lead has been recorded when the user presses another button in the 12-lead interface, such as "print" or "view interpretation". The Tempus Pro monitor may automatically reboot during an intermittent connection with the Tempus Pro smart mount. ii. 12-lead ECG measurements of the Tempus Pro monitor, generated by the standard (louvain) algorithm, could produce inaccurate ECG rhythm and morphology statements. This issue impacts sw versions before vx.36. Recall start date: April 21, 2025
Primary source: https://recalls-rappels.canada.ca/en/alert-recall/tempus-pro-monitor

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.